Q-omics provides the consensus-scored RPS3AP6 profile across patient tissues and cancer cell-line models. RPS3AP6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RPS3AP6 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RPS3AP6 RNA expression shows 16,916 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight THCA, KIRC, and ACC as cancer lineages where RPS3AP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS3AP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS3AP6 survival associations across molecular data types. RPS3AP6 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS3AP6 RNA expression–survival associations across cancer types. High RPS3AP6 expression shows unfavorable associations in ACC, UVM, CESC and LUAD, but favorable associations in THCA and KIRC. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for RPS3AP6 RNA expression.
This table summarizes RPS3AP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS3AP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS3AP6 shows lower tumor expression in UCEC, HNSC, BRCA and BLCA and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher RPS3AP6 RNA expression in tumor versus normal tissue (log2 FC = +0.470, t-test p < 0.001).
This table shows molecular features associated with RPS3AP6 in patient tissues and cancer cell lines. In patient samples, RPS3AP6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
